OR WAIT null SECS
The companies have entered into an agreement to develop processes for a novel immunotherapy protein.
Lonza announced on June 21, 2021 that it has entered into an agreement with SelectImmune Pharma, a pharmaceutical company developing novel immunotherapeutics and alternatives to antibiotics, to collaborate on the development of processes for NlpD, a novel immunotherapy protein. SelectImmune will use Lonza’s early development services such as non-GMP expression and laboratory-scale process development. Work will be carried out at Lonza’s Cambridge, UK site.
“The discovery of NlpD is important and provides new possible strategies to treat infections with immunotherapy. Lonza is a well-known international player, and we look forward to developing the best possible process to have a robust drug candidate in our pipeline,” said Ann Gidner, CEO, SelectImmune Pharma, in a press release.
“De-risking early on can maximize chances of success further down the development and manufacturing pathway. We offer flexible support based on our customers’ unique therapeutic goals and timelines while improving the safety and manufacturability of therapeutics. Our early development services have been supporting companies of various sizes in advancing their drug candidates from late-stage discovery into the clinic for over 10 years. The collaboration with SelectImmune illustrates the value in establishing the foundation on which to build an optimized clinical development program,” said Yvette Stallwood, Head of Applied Protein Services, Lonza, in the press release.